Atherosclerosis in sickle cell disease - A review

International Journal of Angiology

Volumn 18, Issue 2, 2009, Pages 62-66

  Elsharawy, Mohamed A ^a   Moghazy, Khaled M ^a   Shawarby, Mohamed A ^a  

^a IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY   (Saudi Arabia)

Author keywords

Atherosclerosis; Peripheral arterial disease; Sickle cell disease

Indexed keywords

ENDOTHELIN 1; FOLIC ACID; HOMOCYSTEINE; NITRIC OXIDE;

AMINO ACID BLOOD LEVEL; ATHEROSCLEROSIS; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; ENDARTERECTOMY; ENDOTHELIAL DYSFUNCTION; ERYTHROCYTE DISORDER; EXCHANGE BLOOD TRANSFUSION; HEMOLYSIS; HOMOCYSTEINE BLOOD LEVEL; HUMAN; HYPERHOMOCYSTEINEMIA; MAGNETIC RESONANCE ANGIOGRAPHY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVASCULARIZATION; REVIEW; SICKLE CELL ANEMIA; THROMBOCYTE ACTIVATION; THROMBOSIS; VASOCONSTRICTION;

EID: 80053021884     PISSN: 10611711     EISSN: 16155939     Source Type: Journal    
DOI: 10.1055/s-0031-1278326     Document Type: Review

References (54)

1. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994;330:1639-44.
2. Francis RB Jr, Johnson CS. Vascular occlusion in sickle cell disease: Current concepts and unanswered questions. Blood 1991;77:1405-14.
3. Elsharawy MA, Moghazy KM. Peripheral arterial lesions in patient with sickle cell disease. Eur J Vasc Endovasc Surg Extra 2007;14:15-8.
4. Stuart MJ, Setty BN. Sickle cell acute chest syndrome: Pathogenesis and rationale for treatment. Blood 1999;94:1555-60. (Pubitemid 29411305)
5. Gladwin MT, Kato GJ. Cardiopulmonary complications of sickle cell disease: Role of nitric oxide and hemolytic anemia. Hematology Am Soc Hematol Educ Program 2005:51-7.
6. Morris CR, Kato GJ, Poljakovic M, et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA 2005;294:8-90.
7. Lipowsky HH, Sheikh NU, Katz DM. Intravital microscopy of capillary hemodynamics in sickle cell disease. J Clin Invest 1987;80:117-27. (Pubitemid 17097524)
8. Rodgers GP, Schechter AN, Noguchi CT, Klein HG, Nienhuis AW, Bonner RF. Periodic microcirculatory flow in patients with sicklecell disease. N Engl J Med 1984;311:1534-8. (Pubitemid 15223252)
9. Fitch RM, Vergona R, Sullivan ME, Wang YX. Nitric oxide synthase inhibition increases aortic stiffness measured by pulse wave velocity in rats. Cardiovasc Res 2001;51:351-8. (Pubitemid 32695546)
10. Aessopos A, Farmakis D, Tsironi M, et al. Endothelial function and arterial stiffness in sickle-thalassemia patients. Atherosclerosis 2007;191:427-32. (Pubitemid 46400706)
11. Garg UC, Hassid A. Nitric oxide-generating vasodilators inhibit mitogenesis and proliferation of BALB/C 3T3 fibroblasts by a cyclic GMP-independent mechanism. Biochem Biophys Res Commun 1990;171:474-9. (Pubitemid 20283231)
12. Sarkar R, Webb RC, Stanley JC. Nitric oxide inhibition of endothelial cell mitogenesis and proliferation. Surgery 1995;118:274-9.
13. Lau YT, Ma WC. Nitric oxide inhibits migration of cultured endothelial cells. Biochem Biophys Res Commun 1996;221:670-4.
14. Faller D. Endothelial cell responses to hypoxic stress. Clin Exp Pharmacol Physiol 1999;26:74-84. (Pubitemid 29051349)
15. Ergul S, Brunson CY, Hutchinson J, et al. Vasoactive factors in sickle cell disease: In vitro evidence for endothelin-1-mediated vasoconstriction. Am J Hematol 2004;76:245-51. (Pubitemid 38828844)
16. Peacock AJ, Dawes KE, Shock A, Gray AJ, Reeves JT, Laurent GJ. Endothelin-1 and endothelin-3 induce chemotaxis and replication of pulmonary artery fibroblasts. Am J Respir Cell Mol Biol 1992;7:492-9.
17. Dzau VJ, Gibbons GH. Endothelium and growth factors in vascular remodeling of hypertension. Hypertension 1991;18:115-21.
18. Kariya K, Kawahara Y, Araki S, Fukuzaki H, Takai Y. Antiproliferative action of cyclic GMP-elevating vasodilators in cultured rabbit aortic smooth muscle. Atherosclerosis 1989;80:143-7. (Pubitemid 20008396)
19. Francis RB. Large-vessel occlusion in sickle cell disease: Pathogenesis, clinical consequences, and therapeutic implications. Med Hypotheses 1991;35:88-95.
20. Moritani T, Hiwatashi A, Shrier DA, Wang HZ, Numaguchi Y, Westesson PL. CNS vasculitis and vasculopathy: Efficacy and usefulness of diffusion-weighted echoplanar MR imaging. Clin Imaging 2004;28:261-70. (Pubitemid 38916578)
21. de Chadarevian JP, Balarezo FS, Heggere M, Dampier C. Splenic arteries and veins in pediatric sickle cell disease. Pediatr Dev Pathol 2001;4:538-44. (Pubitemid 33051816)
22. den Heijer M, Koster T, Blom HJ, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996;334:759-62. (Pubitemid 26089357)
23. Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: An independent risk factor for vascular disease. N Engl J Med 1991;324:1149-55.
24. Huang T, Yuan G, Zhang Z, Zou Z, Li D. Cardiovascular pathogenesis in hyperhomocysteinemia. Asia Pac J Clin Nutr 2008;17:8-16.
25. Lowenthal EA, Mayo MS, Cornwell PE, Thornley-Brown D. Homocysteine elevation in sickle cell disease. J Am Coll Nutr 2000;19:608-12.
26. Houston PE, Rana S, Sekhsaria S, Perlin E, Kim KS, Castro O. Homocysteine in sickle cell disease: relationship to stroke. Am J Med 1997;103:192-6. (Pubitemid 27413401)
27. Lindenbaum J, Klipstein FA. Folic acid deficiency in sickle-cell anemia. N Engl J Med 1963;269:875-82.
28. Malinow MR, Axthelm MK, Meredith MJ, MacDonald NA, Upson BM. Synthesis and transsulfuration of homocysteine in blood. J Lab Clin Med 1994;123:421-9.
29. Jennings LK. Role of platelets in atherothrombosis. Am J Cardiol 2009;2(3 Suppl):4A-10A.
30. Wun T, Paglieroni T, Rangaswami A, et al. Platelet activation in patients with sickle cell disease. Br J Haematol 1998;100:741-9. (Pubitemid 28126109)
31. Lee SP, Ataga KI, Orringer EP, Phillips DR, Parise LV. Biologically active CD40 ligand is elevated in sickle cell anemia: Potential role for platelet-mediated inflammation. Arterioscler Thromb Vasc Biol 2006;26:1626-31. (Pubitemid 44288993)
32. André P, Nannizzi-Alaimo L, Prasad SK, Phillips DR. Plateletderived CD40L: The switch-hitting player of cardiovascular disease. Circulation 2002;20:896-9. (Pubitemid 34925319)
33. Bennett JS. Vasoocclusion in sickle cell anemia: Are platelets really involved? Arterioscler Thromb Vasc Biol 2006;26:1626-31.
34. Graham JK, Mosunjac M, Hanzlick RL, Mosunjac M. Sickle cell lung disease and sudden death: A retrospective/prospective study of 21 autopsy cases and literature review. Am J Forensic Med Pathol 2007;28:168-72. (Pubitemid 47164700)
35. Stockman JA, Nigro MA, Mishkin MM, Oski FA. Occlusion of large cerebral vessels in sickle cell anemia. N Eng J Med 1972;287:846-9.
36. Rothman SM, Fulling KH, Nelson JS. Sickle cell anemia and central nervous system infarction: A neuropathological study. Ann Neurol 1986;20:684-90. (Pubitemid 17207642)
37. Moran CJ, Siegel MJ, DeBaun MR. Sickle cell disease: Imaging of cerebrovascular complications. Radiology 1998;206:311-21. (Pubitemid 28112942)
38. Sesier Y, Hartshorne T, Thrush A, Nydahi S, Bolia A, London NJM. A prospective comparison of lower limb colour-coded duplex scanning with arteriography. Eur J Vasc Endovasc Surg 1996;11:170-5. (Pubitemid 26120470)
39. Elsharawy MA, Moghazy KM. Can multi-detector computed tomographic angiography replace conventional angiography prior to lower extremity arterial reconstruction? Acta Chir Belg 2006;106:193-8. (Pubitemid 43709763)
40. de Vries M, Ouwendijk R, Flobbe K, et al. Peripheral arterial disease: Clinical and cost comparisons between duplex US and contrast-enhanced MR angiography-a multicenter randomized trial. Radiology 2006;240:401-10. (Pubitemid 44098635)
41. Ouwendijk R, Kock MC, van Dijk LC, van Sambeek MR, Stijnen T, Hunink MG. Vessel wall calcifications at multi-detector row CT angiography in patients with peripheral arterial disease: Effect on clinical utility and clinical predictors. Radiology 2006;241:603-8. (Pubitemid 44632909)
42. Heijenbrok-Kal MH, Kock MC, Hunink MG. Lower extremity arterial disease: Multidetector CT angiography meta-analysis. Radiology 2007;245:433-9. (Pubitemid 47612524)
43. Adriaensen ME, Kock MC, Stijnen T, et al. Peripheral arterial disease: Therapeutic confidence of CT versus digital subtraction angiography and effects on additional imaging recommendations. Radiology 2004;233:385-91. (Pubitemid 39423796)
44. Benza RL. Pulmonary hypertension associated with sickle cell disease: Pathophysiology and rationale for treatment. Lung 2008;186:247-54.
45. Pegelow CH, Adams RJ, McKie V, et al. Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. J Pediatr 1995;126:896-9.
46. Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 1998;339:5-11. (Pubitemid 28304491)
47. Aessopos A, Farmakis D, Hatziliami A, et al. Cardiac status in well-treated patients with thalassemia major. Eur J Haematol 2004;73:359-66. (Pubitemid 39349917)
48. Machado RF, Gladwin MT. Chronic sickle cell lung disease: New insights into the diagnosis, pathogenesis and treatment of pulmonary hypertension. Br J Haematol 2005;129:449-64. (Pubitemid 40769895)
49. Brattstrom LE, Israelsson B, Jeppsson JO, Hultberg BL. Folic acid-an innocuous means to reduce plasma homocysteine. Scand J Clin Lab Invest 1988;48:215-21.
50. Badesch DB, McLaughlin VV, Delcroix M, et al. Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:56S-61S. (Pubitemid 38759718)
51. Machado RF, Martyr S, Kato GJ, et al. Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. Br J Haematol 2005;130:445-53. (Pubitemid 43899595)
52. Barnett CF, Machado RF. Sildenafil in the treatment of pulmonary hypertension. Vasc Health Risk Manag 2006;2:411-22. (Pubitemid 46231272)
53. Channick R, Williamson TL. Diagnosis and treatment of pulmonary arterial hypertension Cardiol Clin 2004;22:441-52. (Pubitemid 39078425)
54. Stoney RJ, Reilly LM. Endarterectomy for aortoiliac disease. In: Ernst CG, Stanley JC, eds. Current Therapy in Vascular Surgery. Philadelphia: BC Decker, 1987:157.